STOCK TITAN

Nuvation Bio Inc - NUVB STOCK NEWS

Welcome to our dedicated page for Nuvation Bio news (Ticker: NUVB), a resource for investors and traders seeking the latest updates and insights on Nuvation Bio stock.

Nuvation Bio Inc (NUVB) is a clinical-stage biopharmaceutical company pioneering novel therapies for challenging cancers through innovative platforms like BD2-selective BET inhibitors and Drug-Drug Conjugate technology. This page serves as the definitive source for tracking the company’s progress in oncology research and corporate developments.

Investors and industry observers will find timely updates on clinical trial milestones, regulatory filings, and strategic partnerships. All press releases and news articles are organized to provide clear insights into Nuvation Bio’s work targeting epigenetic regulators and advanced drug delivery systems.

Key content includes updates on lead candidate NUV-868, financial results, and scientific presentations. The page is regularly updated to reflect the most current information about the company’s efforts to develop precision oncology treatments.

Bookmark this page to stay informed about Nuvation Bio’s advancements in creating therapies for tumors resistant to conventional treatments. Check back frequently for verified updates directly from corporate communications and trusted industry sources.

Rhea-AI Summary
Nuvation Bio Inc. (NYSE: NUVB) announces the dosing of the first patient in a Phase 1/2 study of NUV-1511, their first drug-drug conjugate (DDC) to enter the clinic. The study aims to establish the recommended Phase 2 dose for NUV-1511 and evaluate safety, tolerability, pharmacokinetic profile, and clinical activity in patients with various advanced solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.11%
Tags
-
Rhea-AI Summary
Nuvation Bio Inc. reports completion of Phase 1 monotherapy study of NUV-868, determination of MTD, ongoing Phase 1b studies with olaparib and enzalutamide. FDA clearance for NUV-1511 IND application. Strong financial position with $611.2 million in cash and marketable securities as of December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.25%
Tags
-
Rhea-AI Summary
Nuvation Bio Inc. (NYSE: NUVB) announced the appointment of Robert Mashal, M.D. to its Board of Directors. Dr. Mashal, a seasoned biotech industry veteran, will provide valuable insights to advance Nuvation's pipeline. His experience as an investor, operator, and medical oncologist makes him a valuable addition to the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.58%
Tags
management
Rhea-AI Summary
Nuvation Bio Inc. (NUVB) announced FDA clearance of its IND application for NUV-1511, the first clinical candidate from its novel drug-drug conjugate platform. The company anticipates initiating a Phase 1/2 clinical study of NUV-1511 in 1H 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.58%
Tags
-
Rhea-AI Summary
Nuvation Bio Inc. (NUVB) announces the resignation of Chief Financial Officer Jennifer Fox to pursue new opportunities. Ms. Fox seeks later stage development and commercial launch experience, leaving with high regard for the Company. Her resignation is effective November 27, 2023. Executive and finance team members will assume CFO duties and responsibilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.47%
Tags
none
-
Rhea-AI Summary
Nuvation Bio Inc. reports Q3 2023 financial results with cash, cash equivalents, and marketable securities of $619.3 million. Phase 1 monotherapy study of NUV-868 and Phase 1b study of NUV-868 in combination with olaparib or enzalutamide are ongoing. Expect to submit an IND for first Drug-Drug Conjugate (DDC) clinical candidate by year end 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.47%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.55%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.91%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.09%
Tags
Rhea-AI Summary

Nuvation Bio Inc. (NYSE: NUVB) has initiated dosing in its Phase 1b study of NUV-868, targeting advanced solid tumors, in combination with olaparib or enzalutamide. The company also continues to enroll patients in a Phase 1 monotherapy study. Notably, Nuvation Bio plans to submit an IND for an undisclosed Drug-Drug Conjugate (DDC) candidate by the end of 2023. Financially, as of December 31, 2022, the company reported cash, cash equivalents, and marketable securities totaling $661 million. Q4 2022 net loss was $20.8 million, or $(0.10) per share, a decrease from $25.1 million, or $(0.12) per share, year-over-year, yet annual losses increased to $104.2 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
Nuvation Bio Inc

NYSE:NUVB

NUVB Rankings

NUVB Stock Data

669.15M
247.61M
26.68%
58.95%
7.28%
Biotechnology
Pharmaceutical Preparations
Link
United States
SAN FRANCISCO